|
1
|
World Health Organization (WHO): Cancer
Fact Sheet. 2017
|
|
2
|
Zhang Y, Ren JS, Shi JF, Li N, Wang YT, Qu
C, Zhang Y and Dai M: International trends in primary liver cancer
incidence from 1973 to 2007. BMC Cancer. 15:942015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin MV, King LY and Chung RT: Hepatitis C
virus-associated cancer. Annu Rev Pathol. 10:345–370. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Markowitz GJ, Michelotti GA, Diehl AM and
Wang XF: Inflammatory models drastically alter tumor growth and the
immune microenvironment in hepatocellular carcinoma. Sci Bull
(Beijing). 60:762–772. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kinoshita A, Onoda H, Imai N, Iwaku A,
Oishi M, Fushiya N, Koike K, Nishino H and Tajiri H: Comparison of
the prognostic value of inflammation-based prognostic scores in
patients with hepatocellular carcinoma. Br J Cancer. 107:988–993.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Proctor MJ, Morrison DS, Talwar D, Balmer
SM, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC: An
inflammation-based prognostic score (mGPS) predicts cancer survival
independent of tumour site: A glasgow inflammation outcome study.
Br J Cancer. 104:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lasry A and Ben-Neriah Y:
Senescence-associated inflammatory responses: Aging and cancer
perspectives. Trends Immunol. 36:217–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu J, Yin Z, Cao S, Gao W, Liu L, Yin Y,
Liu P and Shu Y: Systematic review and meta-analysis on the
association between IL-1B polymorphisms and cancer risk. PLoS One.
8:e636542013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chu WM: Tumor necrosis factor. Cancer
Lett. 328:222–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Engelmann H, Holtmann H, Brakebusch C,
Avni YS, Sarov I, Nophar Y, Hadas E, Leitner O and Wallach D:
Antibodies to a soluble form of a tumor necrosis factor (TNF)
receptor have TNF-like activity. J Biol Chem. 265:14497–14504.
1990.PubMed/NCBI
|
|
13
|
Chu WM: Tumor necrosis factor. Cancer
Lett. 328:222–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mocellin S, Rossi CR, Pilati P and Nitti
D: Tumor necrosis factor, cancer and anticancer therapy. Cytokine
Growth Factor Rev. 16:35–53. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zins K, Abraham D, Sioud M and Aharinejad
S: Colon cancer cell-derived tumor necrosis factor-alpha mediates
the tumor growth-promoting response in macrophages by up-regulating
the colony-stimulating factor-1 pathway. Cancer Res. 67:1038–1045.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hagemann T, Robinson SC, Schulz M, Trümper
L, Balkwill FR and Binder C: Enhanced invasiveness of breast cancer
cell lines upon co-cultivation with macrophages is due to TNF-alpha
dependent up-regulation of matrix metalloproteases. Carcinogenesis.
25:1543–1549. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Egberts JH, Cloosters V, Noack A,
Schniewind B, Thon L, Klose S, Kettler B, von Forstner C, Kneitz C,
Tepel J, et al: Anti-tumor necrosis factor therapy inhibits
pancreatic tumor growth and metastasis. Cancer Res. 68:1443–1450.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ferrajoli A, Keating MJ, Manshouri T,
Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl
S, et al: The clinical significance of tumor necrosis factor-alpha
plasma level in patients having chronic lymphocytic leukemia.
Blood. 100:1215–1219. 2002.PubMed/NCBI
|
|
19
|
Aroucha DC, do Carmo RF, Moura P, Silva
JL, Vasconcelos LR, Cavalcanti MS, Muniz MT, Aroucha ML, Siqueira
ER, Cahú GG, et al: High tumor necrosis factor-α/interleukin-10
ratio is associated with hepatocellular carcinoma in patients with
chronic hepatitis C. Cytokine. 62:421–425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang YY, Lo GH, Lai KH, Cheng JS, Lin CK
and Hsu PI: Increased serum concentrations of tumor necrosis
factor-alpha are associated with disease progression and
malnutrition in hepatocellular carcinoma. J Chin Med Assoc.
66:593–598. 2003.PubMed/NCBI
|
|
21
|
Avrămescu CS, Comănescu V, Popescu SN,
Turculeanu A, Bălăşoiu M, Popescu CF and Lungulescu M: Correlations
among the serum levels of some interleukins and the
histopathological aspects in chronic viral hepatitis C. Rom J
Morphol Embryol. 49:57–62. 2008.PubMed/NCBI
|
|
22
|
Yu M, Zhou X, Niu L, Lin G, Huang J, Zhou
W, Gan H, Wang J, Jiang X, Yin B and Li Z: Targeting transmembrane
TNF-α suppresses breast cancer growth. Cancer Res. 73:4061–4074.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Castello G, Scala S, Palmieri G, Curley SA
and Izzo F: HCV-related hepatocellular carcinoma: From chronic
inflammation to cancer. Clin Immunol. 134:237–250. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bulló M, García-Lorda P, Megias I and
Salas-Salvadó J: Systemic inflammation, adipose tissue tumor
necrosis factor, and leptin expression. Obes Res. 11:525–531. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Carswell EA, Old LJ, Kassel RL, Green S,
Fiore N and Williamson B: An endotoxin-induced serum factor that
causes necrosis of tumors. Proc Natl Acad Sci USA. 72:3666–3670.
1975. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Balkwill F: Tumour necrosis factor and
cancer. Nat Rev Cancer. 9:361–371. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kulbe H, Thompson R, Wilson JL, Robinson
S, Hagemann T, Fatah R, Gould D, Ayhan A and Balkwill F: The
inflammatory cytokine tumor necrosis factor-alpha generates an
autocrine tumor-promoting network in epithelial ovarian cancer
cells. Cancer Res. 67:585–592. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou X, Zhou S, Li B, Li Q, Gao L, Li D,
Gong Q, Zhu L, Wang J, Wang N, et al: Transmembrane TNF-α
preferentially expressed by leukemia stem cells and blasts is a
potent target for antibody therapy. Blood. 126:1433–1442. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Swartz MA, Iida N, Roberts EW, Sangaletti
S, Wong MH, Yull FE, Coussens LM and DeClerck YA: Tumor
microenvironment complexity: Emerging roles in cancer therapy.
Cancer Res. 72:2473–2480. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Whiteside TL: The tumor microenvironment
and its role in promoting tumor growth. Oncogene. 27:5904–5912.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Trédan O, Galmarini CM, Patel K and
Tannock IF: Drug resistance and the solid tumor microenvironment. J
Natl Cancer Inst. 99:1441–1454. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ostman A: The tumor microenvironment
controls drug sensitivity. Nat Med. 18:1332–1334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao X, He Y, Gao J, Fan L, Li Z, Yang G
and Chen H: Caveolin-1 expression level in cancer associated
fibroblasts predicts outcome in gastric cancer. PLoS One.
8:e591022013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao X, He Y and Chen H: Autophagic tumor
stroma: Mechanisms and roles in tumor growth and progression. Int J
Cancer. 132:1–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben
T, Ozdoğan M, Artaç M, Altunbaş H, Akan I and Savaş B: Tumour
necrosis factor-alpha, interleukin-6, and fasting serum insulin
correlate with clinical outcome in metastatic breast cancer
patients treated with chemotherapy. Cytokine. 27:58–65. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Karayiannakis AJ, Syrigos KN,
Polychronidis A, Pitiakoudis M, Bounovas A and Simopoulos K: Serum
levels of tumor necrosis factor-alpha and nutritional status in
pancreatic cancer patients. Anticancer Res. 21:1355–1358.
2001.PubMed/NCBI
|
|
38
|
Adams GP and Weiner LM: Monoclonal
antibody therapy of cancer. Nat Biotechnol. 23:1147–1157. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mitoma H, Horiuchi T, Tsukamoto H,
Tamimoto Y, Kimoto Y, Uchino A, To K, Harashima S, Hatta N and
Harada M: Mechanisms for cytotoxic effects of anti-tumor necrosis
factor agents on transmembrane tumor necrosis factor
alpha-expressing cells: Comparison among infliximab, etanercept,
and adalimumab. Arthritis Rheum. 58:1248–1257. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Horiuchi T, Mitoma H, Harashima SI,
Tsukamoto H and Shimoda T: Transmembrane TNF-alpha: Structure,
function and interaction with anti-TNF agents. Rheumatology
(Oxford). 49:1215–1228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sethi G, Sung B and Aggarwal BB: TNF: A
master switch for inflammation to cancer. Front Biosci.
13:5094–5107. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou C, Nitschke AM, Xiong W, Zhang Q,
Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L, Yu D, et al:
Proteomic analysis of tumor necrosis factor-alpha resistant human
breast cancer cells reveals a MEK5/Erk5-mediated
epithelial-mesenchymal transition phenotype. Breast Cancer Res.
10:R1052008. View Article : Google Scholar : PubMed/NCBI
|
